Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05404945
Title Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Virginia
Indications

Hodgkin's lymphoma

Therapies

Dacarbazine + Doxorubicin + Pembrolizumab + Vinblastine

Brentuximab vedotin + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.